Crimson Publishers Publish With Us Reprints e-Books Video articles


Modern Approaches in Drug Designing

Plasma Versus Saliva Therapeutic Drug Monitoring of Mycophenolate in Jordanian Patients with Nephrotic Syndrome

Submission: March 25, 2024;Published: April 16, 2024

ISSN : 2576-9170
Volume 4 Issue 3


Mycophenolate Mofetil (MF) is an ester prodrug of the immunosuppressant Mycophenolic Acid (MPA) and is commonly used for maintenance immunosuppressive therapy in solid organ and stem-cell transplantation, as well as immunological kidney disorders such as Nephrotic syndrome. MPA exerts a specific and reversible cytostatic effect on lymphocytes. The aim of this study is to examine the robustness of employing a non-invasive saliva sample method as a surrogate for Therapeutic Drug Monitoring (TDM) of MF was used to treat nephrotic syndrome in Jordanian individuals. Trough salivary and plasma samples of Mycophenolate mofetil were collected for comparison. Vlidated (LC-MS/MS) method was used to measure MF & MPA levels. Statistical analyses were performed using the ANOVA test. The results of this study showed that saliva MF and MPA levels were less than that of plasma and there is no significant correlation between saliva and plasma levels of MMF and MPA (P>0.05). MF is classified as class three in the salivary excretion classification system.

Keywords:Mycophenolate mofetil; Therapeutic drug monitoring; Salivary excretion classification system; Pk-sim

Get access to the full text of this article